Alnylam Pharmaceuticals (ALNY) PT Raised to $107 at Stifel
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $247.18 -1.78%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 6 | New: 31
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 6 | New: 31
Join SI Premium – FREE
Stifel raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $107.00 (from $83.00) while maintaining a Hold rating following non-eventful earnings.
Analyst Stephen Willey views the initiation of the P3 ENVISION trial as an incremental positive.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Constellation Brands (STZ) PT Lowered to $145 at UBS on Softer Consumer Backdrop
- Viking Therapeutic (VKTX) PT Raised to $87 at Truist Securities
- Pepsico (PEP) PT Lowered to $161 at BNP Paribas Exane, 'Expect Renewed Calls for Greater Urgency in NA'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Stifel, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
